Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Easing the Pain in Monitoring Literature for Adverse Drug Events

Posted on September 20th, 2016 by in Pharmacovigilance

Over the past year, we have heard about the various challenges associated with the cumbersome task of monitoring scientific literature for adverse drug events (AE) from thought leaders on this blog. Pharmacovigilance professionals have written about the literature monitoring and review process, the recent EMA Medical Literature Monitoring initiative, and the importance of literature search strategies. (more…)

Elsevier and Illumina: A meeting of mind and spirit

Posted on August 22nd, 2016 by in Pharma R&D

One of the strongest arguments for using the molecular biology modeling tool Pathway Studio is the rich content underlying its knowledge database. This was driven home recently in a conversation with the DNA/RNA sequencing company Illumina. (more…)

Elsevier and the Cancer Moonshot

Posted on August 17th, 2016 by in Pharma R&D

R_D_Solutions_Blog_Needle_DIGITAL

“Last year, Vice President Biden said that with a new moonshot, America can cure cancer. Last month, he worked with this Congress to give scientists at the National Institutes of Health the strongest resources that they’ve had in over a decade. So tonight, I’m announcing a new national effort to get it done,” said President Obama in his final State of the Union address in January 2016.

(more…)

Introducing ‘The Hive’

Posted on May 4th, 2016 by in Pharma R&D

Fifty-four percent. That’s the percentage of “all active drugs” sourced via open innovation models for the 12 largest biopharma company pipelines in 2014. (more…)

  1. 1
  2. 4
  3. 5
  4. 6